20,751 Shares in Abbott Laboratories $ABT Bought by Shrier Wealth Management LLC

Shrier Wealth Management LLC bought a new position in Abbott Laboratories (NYSE:ABT) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 20,751 shares of the healthcare product maker’s stock, valued at approximately $2,600,000. Abbott Laboratories accounts for approximately 1.0% of Shrier Wealth Management LLC’s holdings, making the stock its 28th largest position.

Several other hedge funds and other institutional investors also recently modified their holdings of ABT. Invesco Ltd. increased its stake in shares of Abbott Laboratories by 51.0% in the third quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock valued at $1,868,718,000 after purchasing an additional 4,713,135 shares during the period. First Trust Advisors LP boosted its position in shares of Abbott Laboratories by 180.7% during the second quarter. First Trust Advisors LP now owns 3,063,443 shares of the healthcare product maker’s stock worth $416,659,000 after buying an additional 1,972,097 shares during the period. Alliancebernstein L.P. grew its holdings in Abbott Laboratories by 51.0% in the 3rd quarter. Alliancebernstein L.P. now owns 5,525,906 shares of the healthcare product maker’s stock worth $740,140,000 after buying an additional 1,865,250 shares in the last quarter. Capital International Investors increased its position in Abbott Laboratories by 2.5% in the 3rd quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker’s stock valued at $8,251,974,000 after acquiring an additional 1,478,076 shares during the period. Finally, Danica Pension Livsforsikringsaktieselskab acquired a new stake in Abbott Laboratories in the 3rd quarter valued at approximately $185,640,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott’s Precision Oncology tests are now integrated into Flatiron Health’s OncoEMR, giving more than 1,600 community cancer centers and ~4,700 providers the ability to order and receive Abbott test results inside their clinical workflow — a direct adoption catalyst for tests such as Oncotype DX, OncoExTra and Oncodetect that can lift diagnostics volume and recurring revenue. Abbott expands access to Precision Oncology
• Positive Sentiment: Abbott is a strategic investor in Whoop’s $575M Series G round (company valued at ~$10.1B). That stake gives Abbott optionality in wearable/consumer biometric data and potential commercial partnerships as Whoop scales globally and eyes an IPO — a complementary play to Abbott’s diabetes and consumer health franchises. Whoop raises $575M, adds Abbott as strategic investor
• Positive Sentiment: Industry research flags the global medical nutrition market growing to ~$31.1B by 2035, with Abbott named among key innovators — a favorable long-term demand backdrop for Abbott’s Nutrition segment once it stabilizes. Global Medical Nutrition Market to Reach USD 31.1 Billion by 2035
• Neutral Sentiment: Analyst note: BTIG trimmed its price target from $140 to $131 but maintained a Buy rating — a modest near-term view change but still a constructive stance implying upside from current levels. BTIG lowers ABT price target
• Neutral Sentiment: Recent analyst and media coverage highlights a mixed fundamental picture: Nutrition sales have pressured near-term growth, but Medical Devices (including FreeStyle Libre CGM and structural heart/electrophysiology businesses) remain strong; management is executing turnaround plans and pursuing the Exact Sciences acquisition — important long-term catalysts but with near-term execution risk. A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?
• Negative Sentiment: Price action & volatility: recent trading showed a pullback to near 52‑week lows amid sector rotation and nutrition weakness, which has pressured sentiment even though core businesses remain solid. Short-term selling and investor rotation remain risks. Abbott (ABT) Dips More Than Broader Market

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, VP John A. Jr. Mccoy sold 585 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $67,614.30. Following the transaction, the vice president owned 24,628 shares of the company’s stock, valued at approximately $2,846,504.24. This represents a 2.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the company’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $102,288.30. Following the sale, the executive vice president directly owned 146,377 shares of the company’s stock, valued at approximately $16,918,253.66. This represents a 0.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 3,055 shares of company stock valued at $353,097 in the last 90 days. 0.46% of the stock is owned by corporate insiders.

Abbott Laboratories Trading Up 0.7%

Shares of Abbott Laboratories stock opened at $102.59 on Wednesday. The business has a fifty day simple moving average of $110.05 and a 200-day simple moving average of $121.57. Abbott Laboratories has a fifty-two week low of $100.88 and a fifty-two week high of $139.06. The firm has a market cap of $178.68 billion, a price-to-earnings ratio of 27.58, a price-to-earnings-growth ratio of 1.63 and a beta of 0.74. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The firm had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. During the same period in the previous year, the company earned $1.34 earnings per share. Abbott Laboratories’s revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, equities analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 67.74%.

Analyst Ratings Changes

ABT has been the subject of a number of analyst reports. Oppenheimer reduced their price target on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Royal Bank Of Canada cut their price objective on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Raymond James Financial reduced their price objective on shares of Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Piper Sandler decreased their target price on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating for the company in a research report on Friday, January 23rd. Finally, Leerink Partners dropped their price target on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating on the stock in a research report on Friday, January 30th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $135.68.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.